Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | PIK3C2B | O00750 | 4/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491012 | 0.93 | BCL2 (0.40) | BCL2MCL1PLA2G2APIK3C2BAGTR1 | |
| SCHEMBL7195514 | 0.92 | PIK3C2B (0.40) | BCL2MCL1PIK3C2BAGTR1AGTR2 | |
| SCHEMBL6489585 | 0.91 | BCL2 (0.48) | BCL2MCL1PLA2G2APIK3C2BDCTPP1 | |
| SCHEMBL6491236 | 0.87 | ALOX5AP (0.45) | BCL2MCL1PLA2G2A | |
| SCHEMBL6501134 | 0.87 | BCL2 (0.47) | BCL2MCL1PLA2G2APIK3C2B | |
| SCHEMBL6497244 | 0.85 | BCL2 (0.44) | BCL2MCL1PLA2G2APIK3C2BAGTR1 | |
| SCHEMBL6500552 | 0.85 | MRGPRX4 (0.49) | BCL2MCL1PLA2G2APIK3C2B | |
| SCHEMBL6487163 | 0.84 | MCL1 (0.42) | MCL1PLA2G2A | |
| SCHEMBL6499333 | 0.83 | BCL2 (0.50) | BCL2MCL1PLA2G2APIK3C2B | |
| SCHEMBL6489324 | 0.83 | BCL2 (0.42) | BCL2MCL1PLA2G2APIK3C2BAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | claimed |
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | BCL2 774/4885MCL1 806/4885PLA2G2A 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.